STUDY QUESTION: Do serum levels of anti-Müllerian hormone (AMH) change in women of reproductive age following dietary and surgery-induced weight loss?
Introduction
Obesity is a major health problem globally, and affecting female fertility negatively (Brewer and Balen, 2010) . In Sweden, 75% of patients seeking surgical treatment for obesity are women, half of those in reproductive age (18-40 years) (SOReg, 2012) . Laparoscopic Rouxen-Y gastric bypass (RYGB) is currently the most common surgical treatment for morbid obesity and gives a loss of around 80% of excess body weight, being reached in~1-1½ years. Bariatric surgery has been shown to normalize menstrual patterns (Teitelman et al., 2006) and improve ovulation, in particular in patients with polycystic ovary syndrome (PCOS) (Eid et al., 2005) . Hence, fertility has been suggested to improve after bariatric surgery (Maggard et al., 2008) .
In women, anti-Müllerian hormone (AMH) is produced in antral and pre-antral follicles, there acting as the gatekeeper that limits follicular growth by inhibiting initial follicle recruitment and diminishing FSH sensitivity in growing follicles (Dewailly et al., 2014 ). Assessment of serum AMH level is therefore widely used to evaluate the ovarian reserve and the possible response to ovarian hyperstimulation prior to assisted reproduction (Broer et al., 2013; Brodin et al., 2015) . AMH has previously been reported to have a weak negative correlation to BMI in women with PCOS, but not in women without this diagnosis (Cui et al., 2014; Lefebvre et al., 2017) .
A decrease in levels of AMH after bariatric surgery has been reported (Merhi et al., 2008) , a finding that does not seem to fit with the reported improved fertility following bariatric surgery. The aim of this study was to evaluate changes in serum levels of AMH and sexhormones following weight loss first achieved by very low-calorie diet (VLCD) and then the more pronounced weight-loss after bariatric surgery.
Materials and Methods

Patient recruitment and ethical approval
After being referred for bariatric surgery based on the criteria of the European guidelines (Fried et al., 2008) , 48 women aged 18-35 years were included in the study. The protocol was approved by the Lund University Ethics committee.
Study design
At baseline (BL) blood samples were collected, and the women were examined for height and weight. A preoperative target weight corresponding to a 5% reduction of total body weight was set, in order to reduce liver size (Colles et al., 2006) . This was achieved using a VLCD, median length of time between BL and operation was 50 days. Blood samples and weight were then collected the day before operation, and the women filled out a questionnaire with five questions regarding current contraception, length of menstrual cycle, previous difficulties to conceive, having been diagnosed with PCOS, and any experience of hirsutism. RYGB was performed laparoscopically in all patients as previously described (Aghajani et al., 2012) . The 6 and 12 months postoperatively blood samples were collected, after 12 months weight was also measured.
Biochemical measurements
All blood samples were drawn independently of menstrual cycle day, and analysed at the same laboratory fresh, or aliquoted and frozen, and then analysed within 7 days. Androstenedione, Dehydroepiandrosterone sulphate (DHEAS) Estradiol, FSH, LH, sex hormone-binding globulin (SHBG) and testosterone were analysed by two-step Electro Chemi Luminiscence Immunoassay (ECLI) on Cobas TM (Roche Diagnostics, Mannheim, Germany). AMH was analysed by two versions of the AMH Gen II ELISA kit (Beckman Coulter, Chaska, MN, USA), using a conversion factor based on internal data in analogy with a previously reported algorithm (Hyldgaard et al., 2015) .
Statistics
Intra-individual variation for the different time points was calculated using the Wilcoxon test for paired data. For comparison of preoperative and 12 months postoperative AMH levels, the former were reduced by 5.6% to compensate for age-related decline (Bentzen et al., 2013) . Mann-Whitney U-test was used to analyse differences between subgroups, and linear regression was used to examine associations. Mixed model was used to adjust for confounders. Two-tailed P-values were used, and the level for statistical significance was set at P < 0.05. Analyses were performed using the SPSS Statistics 23 (IBM, Chicago, IL, USA) and Stata Statistical Software: Release 14 (StataCorp, College Station, TX, USA).
Results
Median AMH levels were significantly higher after the initial VLCD period, 35.0 pmol/L as compared with 30.0 pmol/L at BL. Median AMH at 6 and 12 months postoperatively were significantly lower compared with BL, 19.5 and 18.0 pmol/L, respectively (P = 0.001 for both comparisons). Free androgen index (FAI) also exhibited significant alterations related to the obesity treatment. Results are presented in Table I . Based on the answers of the questionnaire the women were categorized as 'suspected PCOS' (n = 10) if they previously had been given this diagnosis or if they fulfilled two of the three Rotterdam criteria (ESHRE and Group, 2004) . There was no difference between the group of patients with 'suspected PCOS', and those without, neither in terms of change in AMH nor in weight reduction, P = 0.6 and P = 0.7, respectively.
Discussion
The AMH concentration rose during VLCD preoperatively but was at 12 months postoperatively significantly lower (P < 0.0005) than could be explained by a 5.6% annual decline in AMH levels (Bentzen et al., 2013) . The AMH reduction is in line with the results of previous studies (Merhi et al., 2008; Bhandari et al., 2016; Chiofalo et al., 2017) , where AMH levels decreased significantly postoperatively. Also the reduction in testosterone levels was in accordance with a previous study on patients with PCOS (Turkmen et al., 2016) .
We are unable to fully explain the biological mechanisms behind the decrease in AMH and testosterone following bariatric surgery. A limitation is the lack of analyses of other hormones such as TSH, that could influence the sex-hormones. Another limitation for the study is that strict diagnosis of PCOS (Rotterdam criteria, ESHRE and Group, 2004) could not be used since the patients were not examined with vaginal sonography. We tried to assess the possible prevalence of PCOS by using a questionnaire, since these patients might be overrepresented in our material. However, the pattern of changes in AMH in those with 'suspected PCOS' was not different from what was seen in women without signs of PCOS.
AMH has previously been shown to be similarly related to insulin resistance and androgens in women with and without PCOS (Nardo et al., 2009) . Studies on dietary and exercise-related weight-loss in women with PCOS has not shown changes in AMH (Thomson et al., 2009; Nybacka et al., 2013) , whereas hypocaloric diet in combination with sibutramine resulted in improvement in hyperandrogenemia and insulin sensitivity as well as decreased AMH levels (Vosnakis et al., 2012).
Although not being able to draw conclusions from our material, we hypothesize that the observed decline in AMH and testosterone levels after surgery might be related to the improved insulin sensitivity that occurs after RYGB (Pournaras et al., 2016) .
After RYGB it is generally recommended to postpone pregnancy by 12-18 months due to risk of nutritional deficiencies, but concerning patients in their later reproductive period this recommendation has been suggested to be balanced against the declining fertility (Practice Committee of ASRM, 2015) . Decline in AMH levels is usually regarded as a marker of reduced ovarian reserve. In our study AMH levels seems to change unexpectedly in women who have undergone bariatric surgery, indicating that a decline in AMH levels may not necessarily be related to decreased ovarian reserve but might be explained by other mechanisms, e.g. metabolic changes.
In conclusion, we have shown that AMH as well as FAI is significantly reduced 1 year after massive weight-loss induced by RYGB. Further research is needed both to explain the mechanisms and to establish clinical consequences of this finding. Significant as compared with Baseline. c Significant as compared with Expected AMH. PCOS = polycystic ovary syndrome; AMH = anti-Müllerian hormone; SHBG = sex hormone-binding globulin; DHEAS = dehydroepiandrosterone sulphate; BL = baseline; Op = operation.
